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Abstract
Background:  The aim of this study is to assess the association between the Serotonin
Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder (PD).
Methods: This is a systematic review and meta-analysis of case-control studies with unrelated
individuals of any ethnic origin examining the role of the 5-HTTLPR in PD according to standard
diagnostic criteria (DSM or ICD). Articles published in any language between January 1996 and
April 2007 were eligible. The electronic databases searched included PubMed, PsychInfo, Lilacs and
ISI. Two separate analyses were performed: an analysis by alleles and a stratified analysis separating
studies by the quality of control groups. Asymptotic DerSimonian and Laird's Q test were used to
assess heterogeneity. Results of individual studies were combined using the fixed effect model with
respective 95% confidence intervals.
Results: Nineteen potential articles were identified, and 10 studies were included in this meta-
analysis. No statistically significant association between 5-HTTLPR and PD was found, OR = 0.91
(CI95% 0.80 to 1.03, p = 0.14). Three sub-analyses divided by ethnicity, control group quality and
Agoraphobia comorbidity also failed to find any significant association. No evidence of
heterogeneity was found between studies in the analyses.
Conclusion:  Results from this systematic review do not provide evidence to support an
association between 5-HTTLPR and PD. However, more studies are needed in different ethnic
populations in order to evaluate a possible minor effect.
Background
Studies in families have shown that Panic Disorder (PD)
has a familiar pattern: its prevalence is higher in first
degree family members than in control groups [1]. Studies
involving siblings show that PD concordance is higher in
monozygotic than dizygotic twins [2]. These findings pro-
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pose that genetic factors contribute to the pathogenesis of
PD with an estimated heritability of 30–40% [3], whereas
a recent meta-analysis suggests a higher heritability of
48% [4].
Studies on candidate genes for association have been
selected on the basis of the molecular therapeutic drugs
and panic-provoking agents [5]. For instance, the
response shown by panic patients when treated with Sero-
tonin Selective Reuptake Inhibitors (SSRIs) and the wors-
ening when using a serotoninergic agonist suggest a
possible serotoninergic dysfunction in this disorder [2,6].
The serotoninergic transporter gene (5-HTT) is located in
chromosome 17q11.1-q12 [7] and it codes for a mem-
brane protein that reuptakes serotonin from the synaptic
cleft. A size repetition polymorphism has been related to
functionality of the serotoninergic transporter protein.
The polymorphism is a 44 bp insertion or deletion on the
promoter gene region (5 – HTTLPR) resulting in two alle-
les (l-long and s-short). The l allele transcription is two or
three times more efficient than the s allele [8,9]. The s
allele is less active, therefore, resulting in lower serotonin
reuptake and, consequently, in increased serotonin in the
synaptic cleft [10].
Previous studies found a significant association between s
allele and anxiety traits in healthy volunteers [11]. Regard-
ing PD, studies have systematically failed to find any asso-
ciation between this disorder and 5-HTTLPR. This lack of
association could be related to the small sample size of
studies. However, a recent study has raised the possibility
that the l allele could be involved in panic disorder [12].
Although the controversies between 5-HTTLPR in PD may
be related to methodological differences between studies,
such as ethnicity, another limitation is lack of statistical
power [13]. According to Hirschhorn et al. [14], out of
166 studies on gene-disease associations, only six repli-
cated previous findings. Possible causes for this inconsist-
ency include studies with small sample sizes [15,16], as
the most realistic genetic association between a polymor-
phic locus and a disease has been claimed to yield an odds
ratio between 1.1 and 1.5 [17]. Thus at least 1000 subjects
should be required to detect this association, depending
on the prevalence of polymorphism. However, studies
typically report sample sizes from 100 to 300 and rarely
above 1000 subjects [16,18], justifying the use of meta-
analysis to increase power.
The aim of this study is to attempt to answer whether
there is an association between the 5-HTTLPR and PD. As
the s allele of 5-HTTLPR is significantly involved in anxi-
ety traits, the assumption is that this polymorphism
should be involved in PD.
Methods
The search
- Electronic databases: studies were identified through
PubMed (which encompasses Medline, Premedline, and
HelthSTAR), PsychINFO, Lilacs and ISI. The PubMed
search was run using the Mesh terms: ("Serotonin Plasma
Membrane Transport Proteins" [MeSH] OR "5-HTTLPR"
OR "5-HTT" OR "SLC6A4") AND "Panic Disorder"
[MeSH]. In PsychINFO, Lilacs and ISI the following words
were used: "Panic" AND ("serotonin transporter" OR "ser-
otonergic transporter" OR "5-HTT" OR "5-HTTLPR" OR
"SLC6A4"). This search strategy was run in June and rerun
in April 2007, and included only human studies, with no
language restrictions, and a time scope from January 1996
to April 2007, i.e. since the 5-HTTLPR was described by
Heils [9] in 1996.
- Reference cross-checking: the list of references of
included studies was searched looking for additional stud-
ies.
Contact with authors: efforts were made to contact all
research groups of studies included in the analysis to iden-
tify unpublished data. Three authors replied and no addi-
tional study was identified.
Inclusion/Exclusion criteria
Studies reporting the 5-HTTLPR in PD patients of any eth-
nic origin were evaluated by the authors. The inclusion
criteria for this systematic review were: (1) type of studies:
case-control and family-based studies; (2) type of partici-
pants: diagnoses of PD according to standard diagnostic
criteria (DSM or ICD); (3) Hardy-Weinberg Equilibrium
(HWE). Testing for HWE is commonly used for quality
control of large-scale genotyping and is one of the few
ways to identify systematic genotyping errors in unrelated
individuals [19], and its assumption is required for the
allele analysis [20].
Exclusion criteria included (1) studies in which the main
disorders were other than PD; (2) replicated data (a part
of sample used for more than one publication); (3) insuf-
ficient data to perform statistical analysis (unable even
after contacting authors). Regarding replicated data, the
included study was selected based on the sample size and
the availability of information studied in this meta-analy-
sis. Family studies were not included in the analyses
because there is only one study published [21], so no
analysis could be performed.
This meta-analysis methodology was performed accord-
ing to MOOSE (Meta-analysis of Observational Studies in
Epidemiology) group guidelines [22] and stages of this
methodology are presented in a flowchart here in (Figure
1).Behavioral and Brain Functions 2007, 3:41 http://www.behavioralandbrainfunctions.com/content/3/1/41
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Flowchart – Stages of Systematic Review with Meta-analysis Figure 1
Flowchart – Stages of Systematic Review with Meta-analysis.
Planning the Review Blaya C, Salum GA, Lima MS, Segal SL and Manfro GG 
Research question  Is there an association between the 5-HTTLPR and panic disorder? 
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Identification of the need for a 
review 
Several studies with incongruent results and lack of power to detect small effects of this 
polymorphism determine the need for a supportive theoretical construct. 
Conducting a Review
Identification of research  Studies were identified through PubMed, PsychInfo, Lilacs and ISI. The PubMed search 
was run using the Mesh terms: ("Serotonin Plasma Membrane Transport Proteins"[MeSH] 
OR “5-HTTLPR” OR “5-HTT” OR “SLC6A4”) AND "Panic Disorder"[MeSH]. In PsychINFO, 
Lilacs and ISI the following words were used: “Panic” AND (“serotonin transporter” OR 
“serotonergic transporter” OR “5-HTT” OR “5-HTTLPR” OR “SLC6A4”).  Check reference 
section of publications found through our search was used to identify additional studies that 
may have been missed. Contact was tried with all authors in order to identify unpublished 
data  
Study quality assessments and 
study inclusion / exclusion criteria 
Quality assessment criteria 
  Panic Disorder diagnosis (DSM or ICD); 
  Case-control or family-based studies; 
  Hardy-Weinberg Equilibrium (HWE). 
Exclusion criteria
  All patients with major psychiatric disorders other than PD; 
 Replicated  data; 
  Insufficient data to perform statistical analysis.  
Selection of studies  Studies were selected by two authors (CB and GAS) independently. Discrepancies were 
resolved by mutual consent and a third opinion (GGM). Exclusion reasons can be seen 
below the flowchart.  
Included Studies Excluded Studies
Deckert et al.  (German) [34]; 
Deckert et al.  (Italian) [34]; 
Ishiguro et al. [35]; 
Maron et al. [12]; 
Martinez-Barondo et al.  [40] 
Matsushita et al. [36]; 
Ohara et al. [37];  
Olesen et al. [39]; 
Samochowiec et al. [38]; 
Hamilton et al. [21]; 
Kim et al. [41]. 
Hajduk [31]
 ¶; 
Maron et al. [28] *; 
Maron et al. [29]
 ¶; 
Perez et al. [32]
 ‡; 
Perna et al. [26] *; 
Rotondo et al. [25]
π; 
Rotondo et al. [33]
 †; 
Sand et al. [30]
 ¶. 
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Data synthesis and data analysis  Only case-control studies were included in the analyses. The fixed-effect OR was used to 
summarize the results of each single study and the pooled OR. The Q test and I² statistic 
were used to assess heterogeneity between studies. We carried out allelic and genotypic (s 
dominant) tests stratifying each one for ethnicity, control group quality and agoraphobia 
comorbidity, in a total of fourteen analyses sets. 
Reporting and Dissemination
The report 
Analyses  OR (CI95%)  p-value (z)  Heterogeneity Q test ( p-value; I²) 
Allele analysis (s vs. l)  0.91 (0.80-1.03)  0.14 (1.47)  Χ
2
df=9=9.75 (0.37; 7.7%) 
Stratified analysis (s vs. l )       
High Quality  0.88 (0.75 to 1.04)  0.13 (1.52)  Χ
2
df=4=6.51(0.16; 38.6%) 
Caucasian  0.86 (0.74 to 1.01)  0.06 (1.88)  Χ
2
df=5=4.72 (0.45; 0%) 
Agoraphobia comorbidity  0.94 (0.77 to 1.15)  0.57 (0.57)  Χ
2
df=3=5.21 (0.16; 42.1%) 
Recommendations for further 
investigation 
1. Adopt a lifelong perspective of PD; 
2. Appropriate analysis of HWE; 
3. Larger samples to detect the expected small effect of this polymorphism; 
4. An adequate control group with: (a) standardized psychiatric diagnoses (DSM or CIDI, 
for example) assessing the lifelong absence of psychiatric disorders, (b) controls should be 
old enough in order to reduce the possibility for the late onset of the disorder; 
5. An exploratory analysis of the clinical manifestation, considering the nuances of Panic 
Disorder (i.e., agoraphobia, phobic avoidance, panic attacks, etc.) and other ways to 
investigate the heritable portion of PD; 
6. Special attention to comorbidities, considering the significant influence of this 
polymorphism in other psychiatric conditions; 
7. The role evaluation of this polymorphism in other situations such as therapeutic 
responses; 
8. Genotypes must be determined blinding to case-control status in order to minimize the 
risk of a result influenced by an investigator’s preconceptions [13]; 
9. Corrections for multiple comparisons (e.g., Bonferroni correction), in case of multiple 
diagnostic schemes, models of inheritance or multiple genes tests;  
10. Caution on interpretation of results, considering the non-causal pathways, the alpha 
error and the prior probabilities. 
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Getting evidence into practice  The role of 5-HTTLPR in PD still needs more adequate investigation. 
Based on CDR Report, NHS Centre for Reviews and Dissemination, University of York and Cochrane Handbook 
Exclusion reasons: *Without control group; 
¶Replicated data; 
π All patients with major Psychiatric comorbidity other than PD; 
‡ Hardy-
Weinberg departure; 
† Insufficient data;  Behavioral and Brain Functions 2007, 3:41 http://www.behavioralandbrainfunctions.com/content/3/1/41
Page 4 of 10
(page number not for citation purposes)
Data extraction
Data was independently extracted by two investigators
(CB and GAS) using a standardized data extraction form.
Discrepancies were resolved by discussion and if consen-
sus was not achieved the decision was made by another
reviewer (GGM). Data extracted included number of PD
patients and controls for each of the three genotype
groups (ll, ls, ss) in each eligible study. Only data regard-
ing 5-HTTLPR and panic disorder were extracted regard-
less of other polymorphisms, disorders or outcomes
reported in the studies. The male/female ratio, mean age,
predominant ethnicity of the sample and psychiatric
comorbidity were also extracted. Genotype frequencies
were used to calculate whether they deviate significantly
from HWE. In cases where data was not available in the
published reports, authors were contacted directly. The
information was classified as not reported when authors
did not return to at least three contact trials or did not
have this data available.
Statistical analysis
First, an analysis by alleles was performed because this
analysis increases the power to detect differences and is
the most used analysis in the current literature. Secondly,
we analyze the most used model of inheritance (s domi-
nant) to express directly the ll genotype risk [16]. In order
to investigate interaction or confusion between studies, a
stratified analysis was run after separating studies by eth-
nicity, quality of control groups and comorbidity with
Agoraphobia, as recommended by Munafo and Flint [15].
It was considered as high quality control groups those
with appropriate assessment diagnoses. As we performed
fourteen different analyses sets of the same genetic data
we also present correct p-values according to Finner's
modification of the Bonferroni's procedure for multiple
comparisons. Despite being an important analysis, we
could not perform a stratified analysis for comorbidity
with mood disorders and another anxiety disorders
because this data was poorly described in studies included
in this meta-analysis. We choose to perform an explora-
tory analysis because the heritable portion of PD that
could be related to this polymorphism is not yet defined.
Asymptotic DerSimonian and Laird's Q test was used to
assess heterogeneity. Because tests of heterogeneity may
be underpowered to detect heterogeneity between studies
when the number of studies is small [23], we also explore
heterogeneity quantitatively using the I2 statistic [24].
The results of individual studies, as well as the pooled
odds ratio (OR), were synthesized by the fixed effect
model with 95% confidence intervals. The significance of
the pooled OR was determined by the z test. Publication
bias was assessed with a funnel plot (allele analyses). The
analyses were done with Review Manager 4.2.8, software
developed by the Cochrane Collaboration. The Power
Calculator for Genetic Studies software was used in order
to estimate the minimum OR that could be detected in
this meta-analysis.
Forest plot with odds ratio of each study and pooled odds ratio for the association between the s allele and risk of Panic Dis- order Figure 2
Forest plot with odds ratio of each study and pooled odds ratio for the association between the s allele and risk of Panic Dis-
order.
Study
or su
 Panic Disorder  Control  OR (fixed)  Weight  OR (fixed)
b-category  n/N  n/N  95% CI  %  95% CI
 Deckert et al. - G       68/170             74/180  8.48     0.95 [0.62, 1.46]
 Deckert et al. - I       58/146             68/158  7.74     0.87 [0.55, 1.38] 
 Ishiguro et al       115/132            260/300  4.02     1.04 [0.57, 1.91] 
 Matsushita et al.       123/172            328/426 10.57     0.75 [0.50, 1.12] 
 Ohara et al.        36/44             164/220  1.95     1.54 [0.67, 3.50] 
 Samochowiec et al.        60/190            140/404 12.05     0.87 [0.60, 1.26] 
 Maron et al.        94/316            169/430 19.78     0.65 [0.48, 0.89] 
 Martinez-Barondo        78/184            146/348 11.44     1.02 [0.71, 1.46] 
 Olesen et al.        86/208             89/216 10.07     1.01 [0.68, 1.48] 
 Kim et al.       395/488            358/454 13.90     1.14 [0.83, 1.57] 
Total (95% CI) 2050               3136 100.00     0.91 [0.80, 1.03]
Total events: 1113 (Panic Disorder), 1796 (Control)
Test for heterogeneity: Chi² = 9.69, df = 9 (P = 0.38), I² = 7.1%
Test for overall effect: Z = 1.47 (P = 0.14)
 0.1  0.2  0.5  1  2  5  10
 Favours protection  Favours riskBehavioral and Brain Functions 2007, 3:41 http://www.behavioralandbrainfunctions.com/content/3/1/41
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Results
In total, 19 potential publications were identified, and 10
studies were included in this meta-analysis. No analysis
was performed with family-based studies because only
one was found in our search [21]. One study was excluded
because all patients had Bipolar Disorder [25], three stud-
ies were excluded because there were no control groups
[26-28], three studies were excluded because data were
replicated [29-31], one study was excluded due to signifi-
cant deviation of Hardy-Weinberg equilibrium [32] and
one study [33] was excluded due to insufficient data. As
one study [34] had two different sub samples clinically
assessed with different methodologies, it was considered
as two separate studies (Deckert German and Deckert Ital-
ian), resulting in ten studies included in our analysis (fig-
ure 1). The funnel plot suggests a couple of missing
studies with OR higher than 1, but the small number of
included trials does not allow drawing conclusions about
publication bias.
Across all 10 case-control studies investigating 5-HTTLPR
and panic disorder [12,34-41], a total of 1,025 patients
and 1,568 controls were included, totaling 2,050 alleles
among patients and 3,136 alleles between controls. Table
1 depicts data extracted from the included studies. Regard-
ing the allele and stratified analyses, no evidence of heter-
ogeneity was found. The statistics of heterogeneity Q test
and I2 are shown in the figure 2. We found very similar
results between the OR calculated by the random-effects
model and Peto OR.
In the first analysis, including 5,186 alleles, we compared
the 5-HTTLPR allelic distribution between patients with
PD and controls of all ten studies included. The pooled
OR = 0.91 was not significant (CI95% 0.80 to 1.03; z =
1.47; p = 0.14). The results of this analysis are shown in
the forest plot (figure 2). Regarding family studies, we
only identified one in this search [21]. The study had eval-
uated 340 individuals in 45 families with at least three
affected people. No linkage between the 5-HTTLPR and
PD was observed (p = 0.40).
As the included studies have subjects with different eth-
nicity and control groups with different quality, we per-
formed stratified analyses. Only five studies – Maron et al.
[12], Deckert Italian [34], Samochowiec et al. [38], Olesen
et al. [39] and Kim et al. [41] – were classified as having
high quality controls. Results showed no significant asso-
ciation between the s allele and PD in both analyses (high
and low quality). Regarding the ethnic stratified analysis,
no significant association was found in Caucasian or
Asian separated analyses. Some studies evaluated the
comorbidity with Agoraphobia in their exploratory analy-
sis [12,35,38,41] and no significant association was found
in this stratified analysis. Table 2 depicts all these stratified
analyses for the allelic analysis and genotype analysis.
We estimated the minimum OR that could be detected in
this meta-analysis by allelic analysis. Considering a power
of 90%, a PD prevalence of 1.8% in Caucasoid [42], a
mean frequency of s allele of 0.45 in a joint analysis with
the Power Calculator for genetic studies, the minimum
OR that we are capable to found is 1.14.
Discussion
This is the first systematic review between the 5-HTTLPR
and PD and no statistically significant association was
found. In the overall analysis, there was no evidence for
heterogeneity among the studies. This indicates no greater
variation among the studies than could be expected by
chance and provides the validity to the meta-analysis by
suggesting that studies included in this analysis are com-
parable. However, no association was found between this
polymorphism and PD even in all stratified analyses.
The main problem in genetic studies and psychiatric dis-
orders is probably the lack of a phenotype definition.
Clinical diagnoses according to DSM-IV may be heteroge-
neous constructs that combine elements with distinct
genetic influences [43]. Additionally, psychiatric disorders
usually overlap, and comorbidity might be a bias that
impairs some associations. Therefore, some authors are
interested in defining "intermediate" phenotypes that
might have more direct expression of genes influencing a
complex disorder and may have a simpler genetic archi-
tecture [43].
Also, a recently detected genetic variation (16A allele) [44]
in the long allele of 5-HTTLPR has been linked to a lower
expression of the serotonin transporter [45,46]. No study
has evaluated this polymorphism neither in panic disor-
der nor in anxiety traits. Hence, studies should combine
the evaluation of different polymorphisms that influence
the protein expression.
Limitations of this study
The publication bias could not be adequately assessed in
our meta-analysis by the funnel plot due to the small
number of studies available. However, we believe that our
search strategy was comprehensive enough. Moreover,
additional sources of trials like contacting authors of
included trials yield no additional study.
The sample size found in our meta-analysis is below that
which is required to identify associations with minor
effects [17]. In the sub-group analysis the sample size
became even smaller. Thus, further investigation using
larger sample sizes, in which the control group is properly
diagnosed and ethnicity is evaluated, is needed. SuchBehavioral and Brain Functions 2007, 3:41 http://www.behavioralandbrainfunctions.com/content/3/1/41
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Table 1: Included Case-control Studies of 5-HTTLPR and Panic Disorder
Genotype Frequency/
Total (%)
Alelle 
frequency/
Total (%)
HWE reported (df = 1)
Studie
s
Group
s (n)
Male 
(%)
Diagn
osis
Como
rbidit
y
Mean 
Age
Origin ss sl ll s l X2 p
Ishigur
o et al. 
[35]
Panic 
(66)
30 
(45.5)
DSM-
IV
NR 40 Japanes
e
51/66 
(77.3)
13/66 
(19.7)
2/66 
(3)
115/
132 
(87.1)
17/132 
(12.9)
YES 0.986 0.321
Control 
(150)
70 
(46.7)
Not 
report
ed
41 114/
150 
(76)
32/150 
(21.3)
4/150 
(2.7)
260/
300 
(86.7)
40/300 
(13.3)
YES 0.887 0.346
Matsus
hita et 
al. [36]
Panic 
(86)
54 
(62.7)
DSM-
III-R
NR 37.0 Japanes
e
44/86 
(51.2)
35/86 
(40.7)
7/86 
(8.1)
123/
172 
(71.5)
49/172 
(28.5)
YES <0.001 0.992
Control 
(213)
96 
(45.1)
Not 
report
ed
37.7 125/
213 
(58.7)
78/213 
(36.6)
10/213 
(4.7)
328/
426 
(77)
98/426 
(23)
YES 0.242 0.623
Decker
t et al. 
Germa
n [34]
Panic 
(85)
NR DSM-
III-R 
and 
CIDI
Yes 
(Mood) 
; 
Anxiet
y NR
NR Germa
n
12/66 
(14.1)
44/66 
(51.8)
29/66 
(34.1)
68/170 
(40)
102/
170 
(60)
NO 0.523 0.470
Control 
(90)
NR None NR 16/90 
(17.8)
42/90 
(46.7)
32/90 
(35.6)
74/180 
(41.1)
106/
180 
(58.9)
YES 0.118 0.731
Decker
t et al. 
Italian 
[34]
Panic 
(73)
NR DSM-
III-R 
and 
SADS-
LA
Mood 
absent; 
Anxiet
y NR
NR Italian 13/73 
(17.8)
32/73 
(43.8)
28/73 
(38.4)
58/146 
(39.7)
88/146 
(60.3)
NO 0.523 0.470
Control 
(79)
NR DSM-
III-R 
and 
DIS†
NR 12/79 
(15.2)
44/79 
(55.7)
23/79 
(29.1)
68/158 
(43)
90/158 
(57)
YES 1.460 0.227
Ohara 
et al. 
[37]
Panic 
(22)
11 (50) DSM-
IV
Yes 
(Anxiet
y)
35.1 Japanes
e
14/22 
(63.6)
8/22 
(36.4)
0/22 
(0)
36/44 
(81.8)
8/44 
(18.2)
NO 1.086 0.769
Control 
(110)
NR Not 
report
ed
NR 62/110 
(56.4)
40/110 
(36.4)
8/110 
(7.3)
164/
220 
(74.5)
56/220 
(25.5)
NO 0.192 0.661
Samoc
howiec 
et al. 
[38]
Panic 
(95)
24 
(23.8)
CIDI Yes 
(Anxiet
y)
38.7 Polonai
se
10/95 
(10.5)
40/95 
(42.1)
45/95 
(47.4)
60/190 
(31.6)
130/
190 
(68.4)
NO 0.062 0.803
Control 
(202)
54 
(26.7)
ICD-10 35.9 22/202 
(10.9)
96/202 
(47.5)
84/202 
(41.6)
140/
404 
(34.7)
264/
404 
(65.3)
NO 0.492 0.483
Maron 
et al. 
[12]
Panic 
(158)
32 
(20.2)
DSM-
IV 
MINI
Yes 
(Anxiet
y and 
Mood)
38.0 Estonia
n
11/158 
(7)
72/158 
(45.6)
75/158 
(47.5)
94/316 
(29.7)
222/
316 
(70.3)
YES 1.288 0.256
Control 
(215)
56 (26) MINI† 39.8 34/215 
(15.8)
101/
215 
(47)
80/215 
(37.2)
169/
430 
(39.3)
261/
430 
(60.7)
YES 0.051 0.822
Olesen 
et al. 
[39]
Panic 
(104)
28 
(26.9)
DSM-
IV
Yes 
(Anxiet
y)
NR Danish 15/104 
(14.4)
56/104 
(53.8)
33/104 
(31.7)
86/208 
(41.3)
122/
208 
(58.7)
NO 1.263 0.261
Control 
(108)
30 
(27.7)
Clinical 
intervie
w
NR 18/108 
(16.7)
53/108 
(49.1)
37/108 
(34.3)
89/216 
(41.2)
127/
216 
(58.8)
NO 0.018 0.894Behavioral and Brain Functions 2007, 3:41 http://www.behavioralandbrainfunctions.com/content/3/1/41
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studies should focus on exploratory analyses in order to
identify the heritable features that might be related to this
polymorphism. Additionally, we could not perform a sub-
group analysis divided by gender, because only one study
reported this data. Neither did we find any stratified anal-
yses regarding co-morbidity (with alcohol, mood and
anxiety disorders), even though associations between the
5-HTTLPR and these psychiatric disorders have been
reported [30,47,48].
This meta-analysis was carried out with case-control stud-
ies. However, some authors [13] suggest that the results
from this design finding a positive association between
the genome and a disorder could be false. Additionally, a
positive result from a case-control study might be due to
population stratification rather than linkage disequilib-
rium [49] affected by the different disease prevalence and
different marker frequencies in the subpopulation thereby
producing spurious associations [50,51]. The use of
Genomic Control, although with limitations [52], may be
an alternative in analyzing data of case-control studies.
Unfortunately, we could not perform an additional anal-
ysis with family studies because we identified only one
study with this design. Family-based studies have a
unique design in which population stratification is con-
trolled.
Conclusion
In summary, results from this systematic review do not
support the hypothesis of a significant association
between 5-HTTLPR and PD. All the sub-analyses per-
formed failed to find an association between PD and this
polymorphism. However, more studies are needed in dif-
ferent ethnic populations in order to evaluate a possible
minor effect. Finally, the 5-HTTLPR does not seem to play
a major role in the genetics of panic disorder and, there-
fore, other polymorphisms should be investigated.
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Martin
ez-
Barond
o et al. 
[40]
Panic 
(92)
28 
(30.4)
DSM-
IV
NR 35.8 Spanish 18/92 
(19.6)
42/92 
(45.7)
32/92 
(34.8)
78/184 
(42.4)
106/
184 
(57.6)
NO 0.392 0.531
Control 
(174)
67 
(38.5)
Not 
report
ed
38.4 36/174 
(20.7)
74/174 
(42.5)
64/174 
(36.8)
146/
348 
(42)
202/
348 
(58)
NO 2.798 0.094
Kim et 
al. [41]
Panic 
(244)
143 
(58.6)
DSM-
IV
Yes 
(Mood)
36.1 Korean 159/
244 
(65.2)
77/244 
(31.6)
8/244 
(3.3)
395/
488 
(80.9)
93/488 
(19.1)
YES 0.1278 0.721
Control 
(227)
102 
(44.9)
Clinical 
Intervi
ew
33.1 141/
227 
(62.1)
76/227 
(33.5)
10/227 
(4.4)
358/
454 
(78.9)
96/454 
(21.1)
YES 0.0035 0.953
Note: NR, Not reported; HWE, Hardy Weinberg Equilibrium; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; ICD-10, 
International Classification of Diseases; CIDI, Composite International Diagnostic Interview; MINI, MINI International Neuropsychiatric Interview.
†Controls with first degree relatives without psychiatric disorders.
Table 1: Included Case-control Studies of 5-HTTLPR and Panic Disorder (Continued)Behavioral and Brain Functions 2007, 3:41 http://www.behavioralandbrainfunctions.com/content/3/1/41
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Table 2: Results of the overall studies and sub-group studies stratified by ethnicity, quality of control group and comorbidity with 
Agoraphobia
na OR (95% CI) Significance Heterogeneity
Zp - v a l u e F i n n e r ' s  p χ2c p-value I2
Allelic 
analyses (s/
l)b
10 0.91 (0.80–
1.03)
1.47 0.14 0.58 9.75 0.37 7.7%
Ethnicity
Caucasians 6 0.86 (0.74 – 
1.01)
1.88 0.06 0.58 4.72 0.45 0%
Asians 4 1.02 (0.81 – 
1.27)
0.14 0.89 0.92 3.67 0.30 18.3%
Quality of 
Control 
Group
High 
quality 
control 
group
5 0.88 (0.75 – 
1.04)
1.52 0.13 0.58 6.51 0.16 38.6%
Low 
quality 
control 
group
5 0.96 (0.78 – 
1.17)
0.43 0.67 0.76 2.87 0.58 0%
Agoraphobi
a 
comorbidity
With 
Agoraphob
ia
4 0.94 (0.77 – 
1.15)
0.57 0.57 0.69 5.21 0.16 42.4%
Without 
Agoraphob
ia
3 0.80 (0.60 – 
1.08)
1.48 0.14 0.58 2.30 0.32 12.9%
Genotype 
(ls+ss) vs. ll
10 0.87 (0.71 – 
1.06)
1.39 0.17 0.58 7 0.64 0%
Ethnicity
Caucasians 6 0.85 (0.68 – 
1.05)
1.48 0.14 0.58 4.36 0.50 0%
Asians 4 1.01 (0.55 – 
1.86)
0.03 0.98 0.98 2.56 0.46 0%
Quality of 
Control 
Group
High 
quality 
control 
group
5 0.80 (0.63 – 
1.03)
1.76 0.08 0.58 3.72 0.45 0%
Low 
quality 
control 
group
5 1.02 (0.71 – 
1.46)
0.11 0.91 0.93 2.30 0.68 0%
Agoraphobi
a 
comorbidity
With 
Agoraphob
ia
4 0.80 (0.57 – 
1.11)
1.32 0.19 0.58 2.90 0.41 0%
Without 
Agoraphob
ia
3 0.85 (0.51 – 
1.40)
0.65 0.51 0.67 1.18 0.55 0%
Abbreviations: OR, odds ratio (fixed effect); Q, Cochran's x2-based Q statistic test used to assess the heterogeneity; z test used to determine the 
significance of the overall OR; I2, inconsistency; Finner's p-value, adjusted p-value for multiple comparison
a The number of studies included are indicated
b The first allele is the risk allele
c Degrees of freedom = number of studies - 1.Behavioral and Brain Functions 2007, 3:41 http://www.behavioralandbrainfunctions.com/content/3/1/41
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